Malkova I V, Borisova O K, Pavlova M V, Zemlianitskaia E P, Sergeeva T I
Antibiot Khimioter. 1991 Apr;36(4):17-20.
Antibacterial activity of eremomycin, a novel glycopeptide antibiotic, against obligate anaerobic Gram-positive++ bacteria was studied. Eremomycin was shown to inhibit the growth of obligate anaerobic Gram-positive++ cocci and bacteria belonging to Clostridium in rather low concentrations and within narrow ranges of the MIC which was indicative of the antibiotic undoubted advantages. The antibacterial activity of eremomycin was 2 times as high as that of vancomycin and 8 times as high as that of ristomycin with respect to Gram-positive++ anaerobic cocci. Pathogenic strains of Clostridium spp. were 2 to 4 times more sensitive to eremomycin than to vancomycin. A significant property of the novel glycopeptide antibiotic was shown to be its capacity for inhibiting the growth of Gram-positive++ aerobic and obligate anaerobic cocci within the same concentration ranges which might be of importance in monotherapy of mixed aerobic and anaerobic infections.
研究了新型糖肽类抗生素埃瑞霉素对专性厌氧革兰氏阳性++细菌的抗菌活性。结果表明，埃瑞霉素在相当低的浓度和较窄的最低抑菌浓度（MIC）范围内就能抑制专性厌氧革兰氏阳性++球菌以及梭菌属细菌的生长，这表明该抗生素具有明显优势。就革兰氏阳性++厌氧球菌而言，埃瑞霉素的抗菌活性是万古霉素的2倍，是瑞斯托霉素的8倍。梭菌属的致病菌株对埃瑞霉素的敏感性比对万古霉素高2至4倍。这种新型糖肽类抗生素的一个显著特性是，它能够在相同浓度范围内抑制革兰氏阳性++需氧和专性厌氧球菌的生长，这在混合需氧和厌氧感染的单一疗法中可能具有重要意义。
